Panacur Equine Guard 10% w/v Oral Suspension

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Buy It Now

Active ingredient:

Fenbendazole

Available from:

MSD Animal Health UK Limited

ATC code:

QP52AC13

INN (International Name):

Fenbendazole

Pharmaceutical form:

Oral suspension

Prescription type:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Therapeutic group:

Horses

Therapeutic area:

Anthelmintic

Authorization status:

Authorized

Authorization date:

2000-09-05

Summary of Product characteristics

                                Revised: December 2020
A/N: 01394/2020
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur Equine Guard 10% w/v Oral Suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance(s):
% w/v
Fenbendazole
10.000
Excipients
Sodium Methyl Parahydroxybenzoate
0.200
Sodium Propyl Parahydroxybenzoate
0.0216
Benzyl Alcohol
0.4835
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral suspension.
A white, aqueous suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and other equines
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of adult and immature roundworms of the
gastro-intestinal tract in horses and other equines.
The product is also effective for the treatment and control of
encysted mucosal
3rd and 4th stage small strongyle larvae and is also effective against
encysted
inhibited 3rd stage small strogyle larvae in the mucosa.
The
product
is
also
effective
in
controlling
other
immature
and
mature
roundworms including large redworm (_Strongylus edentatus _ and _
Strongylus _
_vulgaris_)
and
migrating
large
redworm,
_Ascarids _
(_Parascaris _
_equorum_),
_Oxyuris_ and _ Strongyloides_ species and benzimidazole susceptible
adult and
immature small strongyles (Cyathostomes).
The product also has an ovicidal effect on nematode eggs.
Revised: December 2020
A/N: 01394/2020
Page 2 of 5
4.3
CONTRA-INDICATIONS
None known.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase
the risk of development of resistance and could ultimately result in
ineffective
therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Under dosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosing
device (if any).
Suspected clinical cases of resistance to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal
                                
                                Read the complete document
                                
                            

Search alerts related to this product